Table 2.

Relationship between the serum FABP4 and FABP6 levels and clinicopathologic features

Variable	FABP4		P value	FABP6		P value
	High expression (n = 50)	Low expression (n = 50)		High expression (n = 50)	Low expression (n = 50)
Age	56.80 ± 8.25	54.0 ± 9.36	0.144	56.16 ± 9.10	54.84 ± 8.68	0.460
Sex
Male	24	29	0.316	28	25	0.548
Female	26	21		22	25
Tumor size (cm)
≤ 5	30	31	0.838	31	30	0.838
> 5	20	19		19	20
Tumor sitea
Left colon	11	5	0.989	10	6	0.716
Right colon	8	5		7	6
Distant organ and lymph node metastasis
Present	4	2	0.674	2	4	0.674
Absent	46	48		48	46
Histologic gradeb
Poorly	10	12	0.887	12	10	0.748
Moderately	35	33		34	34
Well	5	5		4	6
Dukes classificationb
A+B	23	24	0.835	26	21	0.209
C+D	23	22		19	26
TNM classification
0(Tis)	4	4	0.953	5	3	0.443
I+II	24	22		25	21
III+IV	22	24		20	26
Lymphatic permeation
Present	23	19	0.418	23	20	0.545
Absent	27	31		27	30
Neurological invasion
Present	21	17	0.410	22	27	0.317
Absent	29	33		28	23
Vascular invasion
Present	26	24	0.689	13	20	0.137
Absent	24	26		37	30

^aNot counting transverse colon and rectal cancer

^bNot counting carcinoma in situ

Four carcinomas in situ in the FABP4 high and low expression group, respectively, and 5 and 3 carcinomas in situ in the FABP6 high and low expression group, respectively